Polypharmacy, defined as taking five or more drugs, is inadequate in the cardiovascular setting.

Détails

Ressource 1Télécharger: 29777797AM.pdf (601.48 [Ko])
Etat: Public
Version: Author's accepted manuscript
Licence: Non spécifiée
Document(s) secondaire(s)
Télécharger: Supplemental tables.pdf (204.67 [Ko])
Etat: Public
Version: Supplementary document
Licence: Non spécifiée
ID Serval
serval:BIB_1A0984F08046
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Polypharmacy, defined as taking five or more drugs, is inadequate in the cardiovascular setting.
Périodique
Journal of clinical epidemiology
Auteur⸱e⸱s
Abolhassani N., Marques-Vidal P.
ISSN
1878-5921 (Electronic)
ISSN-L
0895-4356
Statut éditorial
Publié
Date de publication
09/2018
Peer-reviewed
Oui
Volume
101
Pages
1-4
Langue
anglais
Notes
Publication types: Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
By how much polypharmacy (defined by number of drugs) differs from polyactive ingredient use (defined by the number of pharmacologically active ingredients) has not been assessed.
To compare the extent of polypharmacy vs. polyactive ingredients among patients taking cardiovascular (CV) medicines.
Prospective, 10-year follow-up study conducted among 880 participants of the CoLaus study taking CV drugs at baseline. Polypharmacy was defined as the use of five or more CV medicines; polyactive ingredient use was defined as the use of five or more pharmacologically active CV ingredients.
The prevalence of polypharmacy increased from 1.4% (0.7-2.4) (prevalence rate [95% confidence interval]) at baseline to 11.9% (9.9-14.3) at follow-up, and the prevalence of polyactive ingredients increased from 2.4% (1.5-3.6) at baseline to almost 17.6% (15.2-20.3) at follow-up. The prevalence of combination drugs increased from 15.7% (13.3-18.3) at baseline to 25.9% (23-28.9) at follow-up, and the prevalence of three-component combination use increased from 0.1% (0.0-0.6) at baseline to 2.3% (1.4-3.5) at follow-up. At baseline, nine of 21 participants on polyactive ingredients were not considered as being on polypharmacy; at follow-up, the rate was 50 of 155 participants.
Among individuals taking CV drugs, polypharmacy as defined by the number of drugs underestimates the prevalence of individuals taking five or more pharmacologically active drugs. Polypharmacy should no longer be based on the number of drugs but on the number of pharmacologically active drugs.
Mots-clé
Adult, Aged, Cardiovascular Agents/therapeutic use, Cardiovascular Diseases/drug therapy, Drug Therapy, Combination/trends, Female, Humans, Independent Living, Male, Middle Aged, Polypharmacy, Prevalence, Prospective Studies, Epidemiology, Pharmacoepidemiology, Prospective study
Pubmed
Web of science
Open Access
Oui
Création de la notice
27/06/2018 17:43
Dernière modification de la notice
24/09/2019 6:11
Données d'usage